Skip to main content
. 2023 Jun 4;13(9):2012–2031. doi: 10.1158/2159-8290.CD-23-0475

Figure 7.

Figure 7. Clinical response in a patient with metastatic salivary gland carcinoma with squamous features and metastases in the lung, liver, and spine. The patient was treated with RLY-4008 at 70 mg once daily, the RP2D. A, Summary of key patient and disease characteristics. B, Liver lesions, left: CT scans of liver metastases on the dome at baseline (top; arrows) and day 64 of RLY-4008 treatment (bottom; arrow indicates remaining lesion with marked reduction in volume) show dramatic regression of lesions. Liver lesions, right: CT scans of diffuse metastatic lesions within the liver parenchyma at baseline and on day 64 of RLY-4008 treatment show a near complete regression of such lesions (circles). Lung lesions: CT scan of lung metastases at baseline and on day 64 of RLY-4008 treatment show overall decrease in lung metastases and near resolution of a lesion (arrow). C, Serum phosphate over the course of treatment with RLY-4008. The shaded area represents the normal range for serum phosphate (0.8–1.5 mmol/L). q.d., once daily; RP2D, recommended phase II dose.

Clinical response in a patient with metastatic salivary gland carcinoma with squamous features and metastases in the lung, liver, and spine. The patient was treated with RLY-4008 at 70 mg once daily, the RP2D. A, Summary of key patient and disease characteristics. B, Liver lesions, left: CT scans of liver metastases on the dome at baseline (top; arrows) and day 64 of RLY-4008 treatment (bottom; arrow indicates remaining lesion with marked reduction in volume) show dramatic regression of lesions. Liver lesions, right: CT scans of diffuse metastatic lesions within the liver parenchyma at baseline and on day 64 of RLY-4008 treatment show a near complete regression of such lesions (circles). Lung lesions: CT scan of lung metastases at baseline and on day 64 of RLY-4008 treatment show overall decrease in lung metastases and near resolution of a lesion (arrow). C, Serum phosphate over the course of treatment with RLY-4008. The shaded area represents the normal range for serum phosphate (0.8–1.5 mmol/L). q.d., once daily; RP2D, recommended phase II dose.